| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Academic Article
|
Subdividing NSCLC: reflections on the past, present, and future of lung cancer therapy.
|
|
Academic Article
|
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
|
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Targeting growth factors and angiogenesis; using small molecules in malignancy.
|
|
Academic Article
|
Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.
|
|
Academic Article
|
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
|
|
Academic Article
|
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
|
|
Academic Article
|
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
|
|
Academic Article
|
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
|
|
Academic Article
|
Update on the role of EGFR inhibitors in cancer therapeutics.
|
|
Academic Article
|
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
|
|
Academic Article
|
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer.
|
|
Academic Article
|
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
|
|
Academic Article
|
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.
|
|
Academic Article
|
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.
|
|
Academic Article
|
Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
|
|
Academic Article
|
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
|
|
Academic Article
|
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
|
|
Academic Article
|
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
|
|
Academic Article
|
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.
|
|
Academic Article
|
Growth and molecular interactions between tamoxifen and trastuzumab.
|
|
Academic Article
|
Induction chemotherapy for head and neck cancer: will history repeat itself?
|
|
Academic Article
|
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Pemetrexed in head and neck cancer: a systematic review.
|